Qiagen N.V:市場シェア分析...市場調査レポートについてご紹介

【英文タイトル】Qiagen N.V Market Share Analysis

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 What Is This Report About? 14
3 Definitions of Markets/Categories Covered 15
3.1 In Vitro Diagnostics 15
3.1.1 Genetic Testing 15
3.1.2 Infectious Immunology 15
4 Company Snapshot 16
4.1 Key Facts 16
4.2 Company Overview 16
4.3 Financial Performance 16
4.4 SWOT Snapshot 16
4.5 Business Overview 17
4.6 Major Products and Services 19
4.6.1 Overview 19
5 History 21
6 SWOT Analysis 26
6.1 Overview 26
6.2 Qiagen N.V. Strengths 27
6.2.1 Broad Product Portfolio 27
6.2.2 Geographical Diversity 27
6.2.3 Strong Research and Development Activities 27
6.3 Qiagen N.V. Weaknesses 27
6.3.1 Pending Litigation 27
6.3.2 Limited Liquidity Position 27
6.4 Qiagen N.V. Opportunities 28
6.4.1 Global In-Vitro Diagnostics Market 28
6.4.2 Substantial Innovative Efforts 28
6.4.3 Strategic Acquisitions and Partnerships 28
6.5 Qiagen N.V. Threats 29
6.5.1 Rapid Technological Changes 29
6.5.2 Intense Competition 29
6.5.3 Stringent Government Regulations 29
6.5.4 Changing Diagnostic Market Conditions 29
7 Competitors 30
8 Competitive Landscape 31
8.1 In Vitro Diagnostics (Genetic Testing), Global, Market Share (%), 2011 31
8.2 Qiagen.N.V, In Vitro Diagnostics (Genetic Testing), by Region, Market Share (2011) 32
8.3 Qiagen.N.V,, In Vitro Diagnostics (Genetic Testing), by Country, Market Share (2011) 33
8.4 In Vitro Diagnostics (Infectious Immunology), Global, Market Share (%), 2011 35
8.5 Qiagen.N.V,, In Vitro Diagnostics (Infectious Immunology), by Region, Market Share (2011) 37
8.6 Qiagen.N.V,, In Vitro Diagnostics (Infectious Immunology), by Country, Market Share (2011) 38
9 Qiagen N.V. Medical Equipment Market Share Analysis by Category 40
9.1 Qiagen N.V., In Vitro Diagnostics, Global, Category Revenue Share (2011) 40
9.2 Qiagen N.V., Asia-Pacific, Category Revenue Share (2011) 42
9.2.1 Qiagen N.V., Australia, Category Revenue Share (2011) 44
9.2.2 Qiagen N.V., China, Category Revenue Share (2011) 46
9.2.3 Qiagen N.V., India, Category Revenue Share (2011) 48
9.2.4 Qiagen N.V., Japan, Category Revenue Share (2011) 50
9.2.5 Qiagen N.V., Other Asia-Pacific, Category Revenue Share (2011) 52
9.3 Qiagen N.V., Europe, Category Revenue Share (2011) 54
9.3.1 Qiagen N.V., France, Category Revenue Share (2011) 56
9.3.2 Qiagen N.V., Germany, Category Revenue Share (2011) 58
9.3.3 Qiagen N.V., Italy, Category Revenue Share (2011) 60
9.3.4 Qiagen N.V., Spain, Category Revenue Share (2011) 62
9.3.5 Qiagen N.V., United Kingdom, Category Revenue Share (2011) 64
9.3.6 Qiagen N.V., Other Europe, Category Revenue Share (2011) 66
9.4 Qiagen N.V., Middle East and Africa, Category Revenue Share (2011) 68
9.5 Qiagen N.V., North America, Category Revenue Share (2011) 70
9.5.1 Qiagen N.V., Canada, Category Revenue Share (2011) 72
9.5.2 Qiagen N.V., United States, Category Revenue Share (2011) 74
9.6 Qiagen N.V., South and Central America, Category Revenue Share (2011) 76
9.6.1 Qiagen N.V., Brazil, Category Revenue Share (2011) 78
9.6.2 Qiagen N.V., Other South and Central America, Category Revenue Share (2011) 80
10 Key Employees 82
11 Key Employee Biographies 83
12 Company Statement 84
13 Locations And Subsidiaries 87
13.1 Head Office 87
13.2 Other Locations & Subsidiaries 87
14 Financial Deals Landscape 89
14.1 Qiagen N.V., Deals Volume Summary, 2007 to YTD 2013 89
15 Qiagen N.V. Detailed Deal Summary 91
15.1 Asset Purchase 91
15.1.1 QIAGEN Completes Acquisition Of Molecular Diagnostics Distribution Business 91
15.1.2 QIAGEN Completes Acquisition Of Distribution Business From Diagnostic Technology 92
15.2 Venture Financing 93
15.2.1 Drug Response Dx Raises Funds Through First Round Of Venture Financing 93
15.2.2 Xagenic Raises $10 Million In Series A Venture Financing 94
15.3 Partnerships 95
15.3.1 IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 95
15.3.2 Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 97
15.3.3 Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 98
15.3.4 Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 99
15.3.5 QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 100
15.3.6 Orion Genomics Enters Into Licensing Agreement With QIAGEN 101
15.3.7 Mayo Medical Labs Enters Into Licensing Agreement With Qiagen 102
15.3.8 Epigenomics Announces Option Licensing Agreement With QIAGEN 103
15.3.9 Epigenomics Enters Into Research Licensing Agreement With QIAGEN 104
15.3.10 Roche Enters Into Licensing Agreement With QIAGEN 105
15.3.11 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 106
15.3.12 QIAGEN Enters Into An Agreement With Roche And Idaho Technology 107
15.3.13 HandyLab Enters Into An Agreement With Qiagen 108
15.3.14 Corbett Life Science Enters Into Licensing Agreement With Applied Biosystems Group 109
15.3.15 QIAGEN Extends Its Agreement With Epigenomics 110
15.3.16 QIAGEN Enters Into Licensing Agreement With Roche Diagnostics 111
15.3.17 QIAGEN And Ortho-Clinical Diagnostics Enter Into Licensing Agreement 112
15.3.18 Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 113
15.3.19 Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 114
15.3.20 Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 115
15.3.21 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 116
15.3.22 QIAGEN Enters Into Co-Development Agreement With Insight Genetics 117
15.3.23 QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 118
15.3.24 QIAGEN Enters Into Co-Development Agreement With Eli Lilly 119
15.3.25 Qiagen Enters Into Co-Development Agreement With Pfizer 120
15.3.26 Olerup Enters Into Co-Marketing Agreement With QIAGEN 122
15.3.27 EyeSense Enters Into An Agreement With QIAGEN 123
15.3.28 QIAGEN Enters Into An Agreement With Abbott 124
15.3.29 QIAGEN Enters Into An Agreement With Genome Diagnostics 125
15.3.30 QIAGEN Enters Into Distribution Agreement With Roche Molecular Systems 126
15.3.31 QIAGEN Enters Into Distribution Agreement With Celera 127
15.3.32 Center for Molecular Medicine Enters Into Research Agreement With QIAGEN 128
15.3.33 QIAGEN Forms Joint Venture With Bio One Capital 129
15.3.34 SEQUENOM Enters Into An Agreement With QIAGEN 130
15.3.35 QIAGEN And Pathway Diagnostics Enter Into Co-Marketing Agreement 131
15.3.36 Biosearch Technologies Enters Into An Agreement With QIAGEN 132
15.3.37 QIAGEN Enters Into Licensing Agreement With BioHelix 133
15.4 Equity Offering 134
15.4.1 QIAGEN Completes Private Placement Of Its Common Stock For $640 Million 134
15.5 Acquisition 136
15.5.1 Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 136
15.5.2 Qiagen Completes Acquisition Of Additional 27% Stake In Ipsogen For $30 Million 137
15.5.3 Qiagen Completes Acquisition Of Cellestis 139
15.5.4 QIAGEN Completes Acquisition Of ESE 141
15.5.5 QIAGEN Completes Acquisition Of SABiosciences 142
15.5.6 QIAGEN Completes Acquisition Of DxS 143
15.5.7 QIAGEN Completes Acquisition Of Explera 145
15.5.8 QIAGEN Acquires Corbett Life Science 146
15.5.9 QIAGEN Acquires Digene 147
15.5.10 QIAGEN Acquires eGene 149
16 Recent Developments 150
16.1 Strategy And Business Planning 150
16.1.1 Nov 28, 2011: QIAGEN Launches Project To Improve Efficiency And Resource Allocation 150
16.1.2 Aug 08, 2011: QIAGEN Opens Taiwan Subsidiary To Further Expand Presence In Asia 151
16.1.3 Jan 27, 2011: QIAGEN Establishes Subsidiary In India To Accelerate Expansion 151
16.1.4 Jun 17, 2010: QIAGEN Expands Partnership With Genome Diagnostics For Development Of New Tests For Applications In Prevention And Personalized Healthcare 152
16.1.5 Sep 08, 2009: Qiagen Inaugurates New Asia Headquarters In Shanghai 153
16.1.6 Jun 16, 2009: Qiagen, Linkmed Sign Agreement To Transfer Distribution Rights 153
16.2 Financial Announcements 154
16.2.1 Nov 04, 2012: Qiagen Reports Revenue Of $304.3m In Q3 2012 154
16.2.2 Jul 24, 2012: Qiagen Reports Revenue Of $307.2m In Q2 2012 155
16.2.3 Apr 25, 2012: QIAGEN Reports Revenue Of $296.4m In Q1 2012 156
16.2.4 Jan 31, 2012: Qiagen Reports Revenue Of $1.2 Billion In 2011 157
16.2.5 Nov 02, 2011: Qiagen Reports Revenue Of $288.9m In Q3 2011 157
16.2.6 Jul 25, 2011: Qiagen Reports Net Sales Of $282.2m In Q2 2011 158
16.2.7 Apr 27, 2011: Qiagen Reports Net Sales Of $264.3m In Q1 2011 159
16.2.8 Jan 31, 2011: Qiagen Reports Net Income Of $222.7 Million In 2010 160
16.2.9 Nov 08, 2010: Qiagen Reports Net Sales Of $274.3m In Q3 2010 161
16.2.10 Aug 09, 2010: Qiagen Reports Net Income Of $38.52 Million In Q2 2010 162
16.2.11 May 03, 2010: Qiagen Reports Net Income Of $33 Million In Q1 2010 163
16.2.12 Feb 08, 2010: Qiagen Reports Net Income Of $137.7 Million In 2009 164
16.2.13 Nov 09, 2009: Qiagen Reports Net Income Of $37.7 Million In Q3 2009 166
16.2.14 Aug 10, 2009: Qiagen Reports Net Income Of $30.9 Million In Q2 2009 168
16.2.15 May 04, 2009: Qiagen Posts Profit Of $24.6 Million In Q1 2009 169
16.2.16 Feb 09, 2009: Qiagen Reports Preliminary 2008 Results 171
16.2.17 Nov 10, 2008: Qiagen Reports 3Q 2008 Results 172
16.2.18 Aug 04, 2008: Qiagen Reports 2Q 2008 Results 174
16.2.19 May 05, 2008: Qiagen Reports Q1 2008 Results 175
16.2.20 Feb 11, 2008: Qiagen Reports Q4 2007 Results 176
16.2.21 Nov 05, 2007: Qiagen Reports Q3 2007 Results 178
16.2.22 Aug 06, 2007: Qiagen Reports Q2 2007 Results 179
16.2.23 May 07, 2007: Qiagen Reports Q1 2007 Results 180
16.2.24 Feb 12, 2007: Qiagen Reports Fiscal Year-End 2006 Results 181
16.2.25 Nov 13, 2006: Qiagen Reports Q3 2006 Results 181
16.2.26 Aug 07, 2006: Qiagen Reports Q2 2006 Results 183
16.3 Research And Development 184
16.3.1 Jan 12, 2009: QIAGEN led-Consortium Launches Project To Improve In-Vitro Diagnostics 184
16.3.2 Dec 03, 2007: QIAGEN, Bio*One Establish Dx Assays 185
16.4 Corporate Communications 185
16.4.1 May 06, 2011: QIAGEN Reaches Milestone With 75 Million Deliveries Of HPV Tests, Announces Strategy Update For QIAensemble Program 185
16.4.2 Dec 14, 2009: Qiagen Added To NASDAQ-100 Index 187
16.4.3 Jan 26, 2009: QIAGEN Appoints New President For QIAGEN Japan 188
16.4.4 Jan 19, 2009: QIAGEN Appoints New Head, Global Regulatory Affairs 188
16.4.5 Sep 18, 2008: Qiagen CEO To Present At UBS Conference 189
16.4.6 May 13, 2008: Qiagen Appoints VP, Molecular Diagnostic Sales For EMEAA 189
16.5 Legal and Regulatory 189
16.5.1 Mar 15, 2012: QIAGEN Welcomes US Guideline Changes To Recommend HPV Testing As Part Of Cervical Cancer Screening 189
16.5.2 Apr 01, 2009: Qiagen Announces CAFC Rejects Third Wave 191
16.5.3 Jan 22, 2009: QIAGEN And Applied Biosystems Settle All Disputes Over Real-Time PCR Thermal Cycler Patents 191
16.6 Product News 192
16.6.1 Jan 15, 2013: Qiagen Submits therascreen EGFR RGQ PCR Kit To FDA To Guide Treatment Decisions For New Investigational Lung Cancer Compound 192
16.6.2 Nov 28, 2012: Qiagen Receives SFDA Approval To Market careHPV Test In China 193
16.6.3 Jul 06, 2012: QIAGEN Receives FDA Approval Of Therascreen KRAS RGQ PCR Kit For Colorectal Cancer 194
16.6.4 Apr 17, 2012: QIAGEN Receives FDA Clearance For artus Infl A/B RG RT-PCR Kit 195
16.6.5 Apr 17, 2012: QIAGEN Receives FDA Clearance For Rotor-Gene Q MDx Instrument 195
16.6.6 Mar 08, 2012: QIAGEN Expands Access To digene HPV Test In China Through Co-Marketing Agreement With KingMed Diagnostics 195
16.6.7 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR Companion Diagnostic To Guide Cancer Treatments 196
16.6.8 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR Companion Diagnostic To Guide Cancer Treatments 197
16.6.9 Jan 09, 2012: QIAGEN And Max Planck Institute For Infection Biology Collaborate To Develop Assay For Active TB Risk In Individuals With Latent Infection 197
16.6.10 Aug 05, 2011: QIAGEN Completes Second US Submission For therascreen KRAS RGQ PCR Kit To Guide Treatment Decisions In Colorectal Cancer 198
16.6.11 Mar 18, 2011: QIAGEN’s Next Generation Hepatitis C Real-time PCR Test Receives SFDA Approval 199
16.6.12 Sep 01, 2010: QIAGEN Launches QIAsymphony RGQ System For Molecular Diagnostics 200
16.6.13 Jul 12, 2010: QIAGEN Announces digene HPV Test Shows Successful Cervical Cancer Control 201
16.6.14 Jul 06, 2010: Qiagen Receives CE Mark For careHPV Test 202
16.6.15 Jan 25, 2010: Qiagen Introduces QIAsymphony AS 202
16.6.16 Jan 18, 2010: Study Finds QIAGEN’s Digene HPV Test Effective In Preventing Invasive Cervical Cancer 203
16.6.17 Sep 10, 2009: QIAGEN Introduces Artus Influenza/H1 RG/LC RT-PCR Kit 204
16.6.18 Jun 03, 2009: QIAGEN’s Next Generation Molecular Diagnostic Receives CE Mark Approval For KRAS Analysis 205
16.6.19 May 25, 2009: QIAGEN Announces Launch Of QIAamp Circulating Nucleic Acid Kit For Extraction Of Free Circulating DNA And RNA Fragments 206
16.6.20 Apr 28, 2009: QIAGEN Provides Screening Tests For Swine Flu Virus 206
16.6.21 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test Compared To Other Methods Including Pap 207
16.6.22 Mar 06, 2009: QIAGEN Supports Cervical Cancer Screening For Underprivileged Chinese Women 208
16.6.23 Nov 10, 2008: QIAGEN Introduces CE-marked Molecular Assay For The Cancer Biomarker K-ras 208
16.6.24 Aug 19, 2008: QIAGEN Unveils Diagnostic Assay In The EU To Detect Genetic Variation Causing Adverse Reactions In AIDS Patients 209
16.6.25 Feb 14, 2008: QIAGEN And Center For Molecular Medicine Create Research Collaboration For Molecular Diagnostic Markers For Breast Cancer, Other Women’s Health Issues 209
16.6.26 May 11, 2007: Digene Research At Clinical Virology Symposium Shows Strides In Multiplex Genotyping Technology Development 210
16.6.27 Apr 19, 2007: Digene Announces Exclusive Marketing and Distribution Agreement with Asuragen, Inc. for Signature Cystic Fibrosis Screening Products. 210
16.7 Product Approvals 210
16.7.1 Jul 06, 2012: QIAGEN Receives FDA Approval Of Therascreen KRAS RGQ PCR Kit For Colorectal Cancer 210
16.7.2 Apr 17, 2012: QIAGEN Receives FDA Clearance For Rotor-Gene Q MDx Instrument 211
16.7.3 Apr 17, 2012: QIAGEN Receives FDA Clearance For artus Infl A/B RG RT-PCR Kit 211
16.7.4 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR Companion Diagnostic To Guide Cancer Treatments 212
16.7.5 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR Companion Diagnostic To Guide Cancer Treatments 212
16.7.6 Mar 18, 2011: QIAGEN’s Next Generation Hepatitis C Real-time PCR Test Receives SFDA Approval 213
16.7.7 Jul 06, 2010: Qiagen Receives CE Mark For careHPV Test 214
16.7.8 Jun 03, 2009: QIAGEN’s Next Generation Molecular Diagnostic Receives CE Mark Approval For KRAS Analysis 214
16.8 Clinical Trials 215
16.8.1 Jul 12, 2010: QIAGEN Announces digene HPV Test Shows Successful Cervical Cancer Control 215
16.8.2 Jan 18, 2010: Study Finds QIAGEN’s Digene HPV Test Effective In Preventing Invasive Cervical Cancer 216
16.8.3 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test Compared To Other Methods Including Pap 217
16.9 Other Significant Developments 218
16.9.1 May 06, 2011: QIAGEN Reaches Milestone With 75 Million Deliveries Of HPV Tests, Announces Strategy Update For QIAensemble Program 218
16.9.2 Oct 12, 2010: QIAGEN, Abbott Enter Into Agreement On Molecular Tests For HIV, HCV And HPV 220
16.9.3 Mar 08, 2010: QIAGEN Extends Support Of Cervical Cancer Screening Program For Underprivileged Chinese Women 221
16.9.4 May 28, 2009: Qiagen Awards Development Contract To Plexus 221
16.9.5 May 28, 2009: Qiagen To Supply Molecular Screening Solutions To Increase Safety Of Blood Donations In Brazil 221
16.9.6 Sep 22, 2008: Osmetech Signs Agreement With Qiagen For QIAplex-Based Respiratory Viral Molecular Test 222
16.9.7 Sep 18, 2008: Qiagen CEO To Present At UBS Conference 223
17 Appendix 224
17.1 Research Methodology 225
17.2 Secondary Research 225
17.3 Primary Research 225
17.4 Models 226
17.5 Forecasts 226
17.6 Expert Panels 226
17.7 GlobalData Consulting 226
17.8 Currency Conversion 227
17.9 Contact Us 228
17.10 Disclaimer 228


【レポート販売概要】

■ タイトル:Qiagen N.V:市場シェア分析
■ 英文:Qiagen N.V Market Share Analysis
■ 発行日:2013年2月28日
■ 調査会社:GlobalData
■ 商品コード:GDATA403160549
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。